Michael J Mcdevitt

US Patent:

6603127, Aug 5, 2003

Filed:

Dec 19, 2000

Appl. No.:

09/647491

Inventors:

David Scheinberg - New York NY
Ronald D. Finn - Rye NY
Dangshe Ma - New York NY
Michael R. McDevitt - New York NY

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

C01G 2900

US Classification:

250432PD, 423 2, 423 6, 423 87, 423249, 210682, 424 111, 252645

Abstract:

The present invention provides a generator capable of producing therapeutic Bismuth-213 doses. Also disclosed are methods of preparing Bismuth-213-labeled compounds using such generator and applications of the labeled compounds.

US Patent:

6683162, Jan 27, 2004

Filed:

Sep 14, 2001

Appl. No.:

09/952756

Inventors:

David Scheinberg - New York NY
Dangshe Ma - Rockville MD
Michael McDevitt - Bronx NY
Paul Borchardt - New York NY

Assignee:

Sloan Kettering Institute of Cancer Research - New York NY

International Classification:

C07F 500

US Classification:

534 11, 424 111, 424 169, 424 149, 514 2, 514183, 514471

Abstract:

The present invention provides functionalized chelants and a method of treating cancerous cells with alpha particles comprising the step of administering a pharmacologically effective dose of an Ac conjugate comprising a functionalized chelant R is independently CHQCO X; Q is independently hydrogen; C1-C4 alkyl or (C1-C2 alkyl) phenyl; X is independently hydrogen; benzyl or C1-C4 alkyl; Z1 is (CH ) Y where n is 1-10 and Y is an electrophilic or nucleophilic moiety and Z2 is R; or, alternatively, Z1 is hydrogen and Z2 is a peptide linker composed of 1-10 amino acids; said Y or said peptide linker covalently attached to an antibody or fragment thereof, or other biologic molecule; or a pharmaceutically acceptable salt thereof, complexed with Ac. These biologic molecule binds to cancerous cells and Ac or its daughters emit alpha particles into said cancerous cells effecting treatment.

US Patent:

7736651, Jun 15, 2010

Filed:

Nov 24, 2000

Appl. No.:

09/721864

Inventors:

David Scheinberg - New York NY, US
Dangshe Ma - New York NY, US
Michael R. McDevitt - Bronx NY, US
George Sgouros - New York NY, US

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

A61K 39/395

US Classification:

4241781, 4241551, 5303871, 5303913

Abstract:

The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha emitting constructs have high specific activity.

US Patent:

8486409, Jul 16, 2013

Filed:

Apr 20, 2010

Appl. No.:

12/799186

Inventors:

David A. Scheinberg - New York NY, US
Michael R. McDevitt - Bronx NY, US
Dangshe Ma - Millwood NY, US
George Sgouros - Ellicott City MD, US

Assignee:

Sloan-Kettering Institute for Cancer Research - New York NY

International Classification:

A61K 39/395
A61K 51/10

US Classification:

4241821, 424 11, 424 149, 424 169, 424 91, 424 93, 424 934, 4241301, 4241381, 4241431, 4241521, 4241551, 4241561, 4241741, 4241781, 424600, 424653, 534 10, 534 11, 252625, 5303913, 5303917

Abstract:

The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.

US Patent:

8540965, Sep 24, 2013

Filed:

Jul 31, 2006

Appl. No.:

11/989672

Inventors:

David A. Scheinberg - New York NY, US
Michael McDevitt - Bronx NY, US
Christophe Antczak - New York NY, US
Debjit Chattopadhyay - Pennington NJ, US
Rena May - Richmond VA, US
Jón Njardarson - Ithaca NY, US
Mark Reid Philips - New York NY, US

Assignee:

Sloan-Kettering Institute for Cancer Research - New York City NY

International Classification:

A61K 49/00

US Classification:

424 91, 424 93, 424 932, 424 9322, 424 934

Abstract:

The present invention provides soluble single wall nanotube constructs functionalized with a plurality of a targeting moiety and a plurality of one or more payload molecules attached thereto. The targeting moiety and the payload molecules may be attached to the soluble single wall carbon nanotube via a DNA or other oligomer platform attached to the single wall carbon nanotube. These soluble single wall carbon nanotube constructs may comprise a radionuclide or contrast agent and as such are effective as diagnostic and therapeutic agents. Methods provided herein are to diagnosing or locating a cancer, treating a cancer, eliciting an immune response against a cancer or delivering an anticancer drug in situ via an enzymatic nanofactory using the soluble single wall carbon nanotube constructs.

US Patent:

20030086868, May 8, 2003

Filed:

Aug 12, 2002

Appl. No.:

10/031792

Inventors:

Dangshe Ma - Millwood NY, US
Michael McDevitt - Bronx NY, US
David Scheinberg - New York NY, US
Jaime Simon - Angleton TX, US
Garry Kiefer - Lake Jackson TX, US
R. Frank - Lake Jackson TX, US
Gyongyi Gulyas - Lake Jackson TX, US

International Classification:

A61K051/00
C07F005/00

US Classification:

424/001650, 534/011000, 540/474000

Abstract:

Actinium-225 (Ac) complexes with functionalized chelants of the formula (I) wherein; each Q is independently hydrogen or ((CHR)COR; Qis hydrogen or (CHR)COR; each R independently is hydrogen, benzyl or C-Calkyl; with the proviso that at least two of the sum of Q and Qmust be other than hydrogen, each Rindependently is hydrogen; C-Calkyl or (C-Calkyl)phenyl; X and Y are each independently hydrogen or may be taken with an adjacent X and Y to form an additional carbon—carbon bond; n is 0 or 1; m is an integer from 0 to 10 inclusive; p is 1 or 2; r is 0 or 1; w is 0 or 1; with the proviso that n is only 1 when X and/or Y form an additional carbon to carbon bond, and the sum of r and w is 0 or 1; L is a linker/spacer group covalently bonded to, and replaces one hydrogen atom of one of the carbon atoms to which it is joined, said linker/spacer group being represented by the formula (1) wherein s is an integer of 0 or 1; t is an integer of 0 to 20 inclusive; Ris an electrophilie or nucleophilic moiety which allows for covalent attachment to an antibody or fragment thereof, or synthetic linker which can be attached to an antibody or fragment thereof, or precursor thereof; and Cyc represents a cyclic aliphatic moiety, aromatic moiety, aliphatic heterocyclic moiety, or aromatic heterocyclic moiety, each of said moieties optionally substituted with one or more groups which do not interfere with binding to an antibody or antibody fragment; with the proviso that when s, t, m, r, and n are 0, then Ris other than carboxyl; their pharmaceutically acceptable salts, their conjugates and the use thereof for radioimmunotherapy is disclosed.

US Patent:

20030175206, Sep 18, 2003

Filed:

Dec 16, 2002

Appl. No.:

10/319978

Inventors:

George Sgouros - New York NY, US
James Thomas - New York NY, US
David Scheinberg - New York NY, US
Michael McDevitt - Bronx NY, US
Stavroula Sofou - New York NY, US

International Classification:

A61K051/00
A61K009/127

US Classification:

424/001110, 424/450000

Abstract:

The present invention provides targeted delivery of alpha particle-emitting radionuclides and their alpha-emitting progeny using liposomal encapsulation to prevent the loss of daughter radionuclides from the targeting vehicle and, therefore, from the tumor site.

US Patent:

20030228258, Dec 11, 2003

Filed:

May 30, 2003

Appl. No.:

10/448647

Inventors:

David Scheinberg - New York NY, US
Michael McDevitt - Bronx NY, US

International Classification:

A61K051/00
C07K014/74

US Classification:

424/001690, 530/350000

Abstract:

The present invention provides a cytotoxic MHC I conjugate comprising a cytotoxic moiety, biotinylated MHC I monomers which each comprise an antigenic peptide and streptavidin, bound to the cytotoxic moiety or to a biotinylated cytotoxic moiety and to the biotinylated MHC I monomers. Alternative constructs comprising a cytotoxic moiety and biotinylated MHC I monomers where each monomer comprises an antibody fragment also are provided. The cytotoxic moiety may comprise an 225Ac radionuclide or other cytotoxin. Further provided are methods of killing CD8T cell clonal populations.